{"entity":{"id":"nct07423585","kind":"trial","name":"Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer","aka":[],"tldr":"A phase 2 trial of tarlatamab in lung cancer, run by Asrar Alahmadi, now recruiting.","summary":"Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer is a phase 2, interventional study registered as NCT07423585 by Asrar Alahmadi, with a registry enrolment figure of 39 participants, started 2026-03-20 and due to reach its primary completion in 2027-12-31. Interventions recorded: Biopsy Procedure; Biospecimen Collection; Computed Tomography; Echocardiography Test; Electronic Health Record Review; Magnetic Resonance Imaging; Multigated Acquisition Scan; Questionnaire Administration; Tarlatamab. Conditions listed: Extensive Stage Lung Small Cell Carcinoma. Primary outcome: 6-month progression-free survival (PFS); Rapid progressive disease (PD) on tarlatamab rate probability (Interim analysis for futility monitoring). Lung eligibility wording from the registry: \", metastatic and/or recurrent) SCLC\". Sites: United States. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT07423585","url":"https://clinicaltrials.gov/study/NCT07423585"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["extensive-stage-sclc"],"sections":[],"technologies":["bispecific-antibody","t-cell-engager"],"targets":[],"drugs":["tarlatamab"],"companies":["amgen"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07423585","phase":"2","setting":"A Front-Line Window-of-Opportunity Phase 2 Study of Tarlatamab (Bispecific T Cell Engager: DLL3-CD3) in Patients With Extensive-Stage Small-Cell Lung Cancer","sponsor":"Asrar Alahmadi","enrolled":39,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07423585/","neighbours":{"cancer":[{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"t-cell-engager","kind":"technology","name":"T-cell engagers (bispecific)","route":"/technologies/t-cell-engager/"}],"drug":[{"id":"tarlatamab","kind":"drug","name":"Tarlatamab","route":"/drugs/tarlatamab/"}],"company":[{"id":"amgen","kind":"company","name":"Amgen","route":"/companies/amgen/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}